133032-61-8Relevant articles and documents
An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists
Iyengar, Rajesh R.,Lynch, John K.,Mulhern, Mathew M.,Judd, Andrew S.,Freeman, Jennifer C.,Gao, Ju,Souers, Andrew J.,Zhao, Gang,Wodka, Dariusz,Doug Falls,Brodjian, Sevan,Dayton, Brian D.,Reilly, Regina M.,Swanson, Sue,Su, Zhi,Martin, Ruth L.,Leitza, Sandra T.,Houseman, Kathryn A.,Diaz, Gilbert,Collins, Christine A.,Sham, Hing L.,Kym, Philip R.
, p. 874 - 878 (2007)
The optimization of potent MCHr1 antagonist 1 with respect to improving its in vitro profile by replacement of the 3,4-methylenedioxy phenyl (piperonyl) moiety led to the discovery of 19, a compound that showed excellent MCHr1 binding and functional potencies in addition to possessing superior hERG separation, CYP3A4 profile, and receptor cross-reactivity profiles.
Carboxamide Compounds and Their Use
-
Page/Page column 26; 30-31, (2010/12/31)
Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.
